Cuprina Holdings (Cayman) Limited Announces Pricing of $12 million Initial Public Offering

Rhea-AI Summary

Cuprina Holdings (CUPR), a biomedical and biotechnology company focused on chronic wound management and cosmeceuticals, has announced the pricing of its Initial Public Offering (IPO). The company is offering 3,000,000 Class A Ordinary Shares at $4.00 per share, with an additional 45-day option for underwriters to purchase up to 450,000 shares.

The IPO is expected to generate gross proceeds of $13.80 million (assuming full exercise of the over-allotment option), before deducting underwriting costs and offering expenses. Trading will commence on NASDAQ under the symbol 'CUPR' on April 10, 2025, with the offering scheduled to close on April 11, 2025. R. F. Lafferty & Co. is serving as the sole book-running manager for the offering.

Positive

• Initial public offering provides access to public capital markets
• Gross proceeds of up to $13.80 million to fund operations
• NASDAQ listing enhances company visibility and credibility

Negative

• Potential shareholder dilution from new share issuance
• Additional dilution possible if over-allotment option is exercised

Insights

Financial Analyst

Cuprina Holdings' $12 million IPO at $4.00 per share represents a significant milestone for this biomedical company, though the offering size is relatively modest compared to typical biotech public debuts. The pricing structure with 3 million shares and a 15% over-allotment option (potentially bringing total proceeds to $13.8 million) suggests careful positioning in what remains a challenging market for small-cap biotech offerings.

The company's focus on chronic wound management products and cosmeceuticals targets growing healthcare needs associated with aging populations and increasing chronic disease prevalence. However, the modest capital raise may limit their ability to fund extensive R&D or commercial expansion in what is typically a capital-intensive sector.

Securing a NASDAQ listing provides Cuprina with important market visibility and potential access to additional capital through future offerings if their initial commercialization efforts prove successful. The $4.00 share price sits at the lower end of typical IPO ranges, potentially reflecting current market conditions or revenue visibility.

For investors, this represents an entry point into a specialized biotech player, though with the typical risks associated with early-stage companies in this sector. The successful IPO execution demonstrates market confidence in their business model, but the proceeds suggest they'll need to be highly strategic with capital deployment to achieve meaningful commercial traction.

SINGAPORE, April 10, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds as well as cosmeceuticals for the health and beauty sector, today announced the pricing of its firm commitment initial public offering of an aggregate 3,000,000 shares of its Class A Ordinary Shares (“the Offering”), all of which are being offered by CUPR at a public offering price of $4.00 per share (“the Offering Price”).

The Company has granted the underwriter a 45-day option to purchase up to an additional 450,000 shares of its Class A Ordinary Shares at the Offering Price, representing 15% of the Class A Ordinary Shares sold in the Offering (“the Over-allotment”).

Assuming that the Over-allotment is exercised, the Company is expected to receive gross proceeds amounting to $13.80 million, before deducting underwriting discounts and commissions and estimated offering expenses.

The shares are expected to begin trading on the NASDAQ Stock Market LLC under the ticker symbol “CUPR” on April 10, 2025. The Offering is expected to close on April 11, 2025, subject to the satisfaction of customary closing conditions.

R. F. Lafferty & Co., Inc. (“R. F. Lafferty”), acted as the sole book-running manager for the Offering. Loeb & Loeb LLP, Lee & Lee, Harney Westwood & Riegels Singapore LLP are acting as U.S., Singapore and Cayman Islands legal counsels to the Company, respectively, and Winston & Strawn LLP is acting as U.S. legal counsel to R. F. Lafferty for the Offering. 

The Offering is being conducted pursuant to the Company’s Registration Statement on Form F-1 (File No: 333-283643) previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (“SEC”) on March 31, 2025. The Offering is being made only by means of a prospectus. Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. Copies of the final prospectus related to the Offering may be obtained, when available, from R. F. Lafferty & Co., Inc., 40 Wall Street, 27th Floor, New York, NY 10005; (212) 293-9090, or by email at offerings@rflafferty.com. In addition, a copy of the final prospectus, when available, relating to the Offering may be obtained via the SEC’s website at www.sec.gov.  

This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

About Cuprina Holdings (Cayman) Limited

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https:// www.cuprina.com.  

Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg

Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email: info@skylineccg.com 

FAQ

What is the IPO price for Cuprina Holdings (CUPR) shares?

Cuprina Holdings priced its IPO at $4.00 per share for 3,000,000 Class A Ordinary Shares.

When will CUPR stock begin trading on NASDAQ?

CUPR shares will begin trading on NASDAQ on April 10, 2025.

How much money will Cuprina Holdings raise from its IPO?

The company expects to raise $13.80 million in gross proceeds if the over-allotment option is fully exercised.

What is the over-allotment option in CUPR's IPO?

Underwriters have a 45-day option to purchase up to 450,000 additional shares at the IPO price of $4.00 per share.

What business sectors does Cuprina Holdings (CUPR) operate in?

CUPR operates in biomedical and biotechnology sectors, focusing on chronic wound management products and cosmeceuticals.